# Telomir Pharmaceuticals, Inc.: financial statements, quarterly

TELO · Nasdaq · CIK 1971532 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/telo.md) · [Financials](/companies/telo/financials.md) · [Filings](/companies/telo/filings.md) · [Insiders](/companies/telo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/telo/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [263](/filings/0001493152-24-044749.md) | [204 d](/filings/0001493152-25-004872.md) | [804](/filings/0001641172-25-010298.md) | [595](/filings/0001641172-25-023970.md) | [627](/filings/0001493152-25-021496.md) | [269 d](/filings/0001493152-26-010625.md) | [337](/filings/0001493152-26-023010.md) | [42.8](/filings/0001493152-26-037854.md) | [760](/filings/0001493152-25-021496.md) | [1,296 d](/filings/0001493152-26-010625.md) | [468](/filings/0001493152-26-023010.md) | [445](/filings/0001493152-26-037854.md) |
| Operating income | $k | not reported | not reported | [1,916](/filings/0001641172-25-010298.md) | not reported | not reported | not reported | [2,188](/filings/0001641172-25-010298.md) | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $k | [757](/filings/0001493152-24-044749.md) | [762 d](/filings/0001493152-24-012049.md) | [4,339](/filings/0001493152-24-018909.md) | [(0.0) d](/filings/0001641172-25-023970.md) | [0.0 d](/filings/0001493152-25-021496.md) | [(0.0) d](/filings/0001493152-26-010625.md) | [0.0](/filings/0001493152-26-023010.md) | [1.3](/filings/0001493152-26-037854.md) | [0.0 d](/filings/0001493152-25-021496.md) | not reported | [1.3](/filings/0001493152-26-023010.md) | [3.0](/filings/0001493152-26-037854.md) |
| Net income | $k | [(1,711)](/filings/0001493152-24-044749.md) | [(9,327)](/filings/0001493152-24-018909.md) | [(6,255)](/filings/0001493152-25-021496.md) | [(1,389)](/filings/0001493152-25-021496.md) | [(5,991)](/filings/0001493152-25-021496.md) | [(2,898) d](/filings/0001493152-26-010625.md) | [(2,180)](/filings/0001493152-26-023010.md) | [(5,070)](/filings/0001493152-26-037854.md) | [(1,102)](/filings/0001493152-25-021496.md) | [(2,061) d](/filings/0001493152-26-010625.md) | [(991)](/filings/0001493152-26-037854.md) | [(1,722)](/filings/0001493152-26-037854.md) |
| Diluted EPS | $ per share | [(0.06)](/filings/0001493152-24-044749.md) | not reported | [(0.23)](/filings/0001641172-25-010298.md) | [0.05](/filings/0001641172-25-023970.md) | [(0.20)](/filings/0001493152-25-021496.md) | not reported | [(0.07)](/filings/0001493152-26-023010.md) | [(0.17)](/filings/0001493152-26-037854.md) | [(0.03)](/filings/0001493152-25-021496.md) | not reported | [(0.03)](/filings/0001493152-26-023010.md) | [(0.79)](/filings/0001493152-26-037854.md) |
| Basic EPS | $ per share | [(0.06)](/filings/0001493152-24-044749.md) | not reported | [(0.23)](/filings/0001641172-25-010298.md) | [0.05](/filings/0001641172-25-023970.md) | [(0.20)](/filings/0001493152-25-021496.md) | not reported | [(0.07)](/filings/0001493152-26-023010.md) | [(0.17)](/filings/0001493152-26-037854.md) | [(0.03)](/filings/0001493152-25-021496.md) | not reported | [(0.03)](/filings/0001493152-26-023010.md) | [(0.79)](/filings/0001493152-26-037854.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | not reported | [1.2](/filings/0001493152-25-004872.md) | [3,274](/filings/0001493152-24-018909.md) | [1,884](/filings/0001493152-24-031606.md) | [835](/filings/0001493152-24-044749.md) | [1,266](/filings/0001641172-25-023970.md) | [403](/filings/0001641172-25-010298.md) | [754](/filings/0001641172-25-023970.md) | [7,329](/filings/0001493152-25-021496.md) | [7,287](/filings/0001493152-26-037854.md) | [5,561](/filings/0001493152-26-023010.md) | [5,170](/filings/0001493152-26-037854.md) |
| Current assets | $k | not reported | [435](/filings/0001493152-25-004872.md) | [3,503](/filings/0001493152-24-018909.md) | [2,102](/filings/0001493152-24-031606.md) | [1,042](/filings/0001493152-24-044749.md) | [1,324](/filings/0001493152-26-010625.md) | [491](/filings/0001641172-25-010298.md) | [830](/filings/0001641172-25-023970.md) | [7,402](/filings/0001493152-25-021496.md) | [7,341](/filings/0001493152-26-037854.md) | [5,790](/filings/0001493152-26-023010.md) | [5,366](/filings/0001493152-26-037854.md) |
| Total assets | $k | not reported | [4,774](/filings/0001493152-25-004872.md) | [3,503](/filings/0001493152-24-018909.md) | [2,102](/filings/0001493152-24-031606.md) | [1,042](/filings/0001493152-24-044749.md) | [1,324](/filings/0001493152-26-010625.md) | [491](/filings/0001641172-25-010298.md) | [830](/filings/0001641172-25-023970.md) | [7,402](/filings/0001493152-25-021496.md) | [7,341](/filings/0001493152-26-037854.md) | [5,790](/filings/0001493152-26-023010.md) | [5,366](/filings/0001493152-26-037854.md) |
| Current liabilities | $k | not reported | [1,336](/filings/0001493152-25-004872.md) | [487](/filings/0001493152-24-018909.md) | [534](/filings/0001493152-24-031606.md) | [600](/filings/0001493152-24-044749.md) | [681](/filings/0001493152-26-010625.md) | [652](/filings/0001641172-25-010298.md) | [348](/filings/0001641172-25-023970.md) | [423](/filings/0001493152-25-021496.md) | [1,428](/filings/0001493152-26-037854.md) | [827](/filings/0001493152-26-023010.md) | [332](/filings/0001493152-26-037854.md) |
| Total liabilities | $k | not reported | [1,336](/filings/0001493152-25-004872.md) | [487](/filings/0001493152-24-018909.md) | [534](/filings/0001493152-24-031606.md) | [600](/filings/0001493152-24-044749.md) | [681](/filings/0001493152-26-010625.md) | [652](/filings/0001641172-25-010298.md) | [348](/filings/0001641172-25-023970.md) | [423](/filings/0001493152-25-021496.md) | [1,428](/filings/0001493152-26-037854.md) | [827](/filings/0001493152-26-023010.md) | [332](/filings/0001493152-26-037854.md) |
| Shareholders' equity | $k | [2,178](/filings/0001493152-24-044749.md) | [3,438](/filings/0001493152-26-010625.md) | [3,017](/filings/0001493152-25-021496.md) | [1,628](/filings/0001493152-25-021496.md) | [442](/filings/0001493152-25-021496.md) | [643](/filings/0001493152-26-037854.md) | [(161)](/filings/0001493152-26-037854.md) | [481](/filings/0001493152-26-037854.md) | [6,979](/filings/0001493152-25-021496.md) | [5,913](/filings/0001493152-26-037854.md) | [4,962](/filings/0001493152-26-037854.md) | [5,033](/filings/0001493152-26-037854.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,003) d](/filings/0001493152-24-044749.md) | [(1,087) d](/filings/0001493152-25-004872.md) | [(1,939)](/filings/0001641172-25-010298.md) | [(1,523) d](/filings/0001641172-25-023970.md) | [(1,002) d](/filings/0001493152-25-021496.md) | [(606) d](/filings/0001493152-26-010625.md) | [(863)](/filings/0001493152-26-023010.md) | [(696) d](/filings/0001493152-26-037854.md) | [(927) d](/filings/0001493152-25-021496.md) | [(1,201) d](/filings/0001493152-26-010625.md) | [(1,774)](/filings/0001493152-26-023010.md) | [(1,012) d](/filings/0001493152-26-037854.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [26.9](/filings/0001493152-24-018909.md) | [27.1](/filings/0001493152-24-031606.md) | [27.1](/filings/0001493152-24-044749.md) | [29.3](/filings/0001641172-25-010298.md) | [29.6](/filings/0001641172-25-023970.md) | [29.6](/filings/0001493152-25-021496.md) | [29.8](/filings/0001493152-26-023010.md) | [30.0](/filings/0001493152-26-037854.md) | [32.4](/filings/0001493152-25-021496.md) | [34.4](/filings/0001493152-26-023010.md) | [60.8](/filings/0001493152-26-037854.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 68,774,956 at 2026-08-12, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037854.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.